Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral cyclophosphamide vs doxorubicin in elderly patients with advanced or metastatic soft tissue sarcoma
2018-000542-20Phase 3Active
- Sponsor
- Unicancer
- Start
- Oct 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in soft tissue sarcoma (STS) comparing Oral cyclophosphamide with Doxorubicin (2 arms). Primary endpoint: Progression-free survival. Started Oct 2020; status: active.
02
Drugs
cyclophosphamidedoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2018-000542-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000542-20.